(Q35009338)

5 August 2017

1 reference

title

Uterine sarcomas: a review (English)

1 reference

5 August 2017

Emanuela D'Angelo

1

1 reference

5 August 2017

Jaime Prat

series ordinal

2

1 reference

5 August 2017

language of work or name

English

0 references

publication date

23 October 2009

1 reference

5 August 2017

1 reference

5 August 2017

volume

116

1 reference

5 August 2017

issue

1

1 reference

5 August 2017

page(s)

131-139

1 reference

Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group study

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.023

Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.023

Uterine leiomyosarcoma: does the primary surgical procedure matter?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.023

Smooth muscle neoplasms of the uterus other than ordinary leiomyoma. A study of 46 cases, with emphasis on diagnostic criteria and prognostic factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.023

Prognostically favorable "mitotically active" smooth-muscle tumors of the uterus. A clinicopathologic study of ten cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.023

Mesenchymal tumors of the uterus VI. Epithelioid smooth muscle tumors including leiomyoblastoma and clear-cell leiomyoma.A clinical and pathologic analysis of 26 cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.023

Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.023

Leiomyosarcoma of the uterus: a clinicopathologic multicenter study of 71 cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.023

The Use of p16 in enhancing the histologic classification of uterine smooth muscle tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.023

Expression of p16 protein in patients with uterine smooth muscle tumors: an immunohistochemical analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.023

Immunohistochemical analysis of p16, p53, and Ki-67 expression in uterine smooth muscle tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.023

MIB-1 (Ki-67), p53, estrogen receptor, and progesterone receptor expression in uterine smooth muscle tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.023

Uterine leiomyosarcomas are characterized by high p16, p53 and MIB1 expression in comparison with usual leiomyomas, leiomyoma variants and smooth muscle tumours of uncertain malignant potential

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.023

p53 immunoreactivity and mutation of the p53 gene in smooth muscle tumours of the uterine corpus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.023

The expression of Ki-67, p53, estrogen and progesterone receptors affecting survival in uterine leiomyosarcomas. A clinicopathologic study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.023

Uterine leiomyosarcomas express KIT protein but lack mutation(s) in exon 9 of c-KIT

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.023

Increased risk of cancer in patients with fumarate hydratase germline mutation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.023

Analysis of fumarate hydratase mutations in a population-based series of early onset uterine leiomyosarcoma patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.023

Comparative clinicopathologic and immunohistochemical analysis of uterine sarcomas diagnosed using the World Health Organization classification system.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.023

Clinical outcome and prognostic factors in 100 cases of uterine sarcoma: experience in Helsinki University Central Hospital 1990-2001.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.023

Prognostic factors and outcome in women with uterine sarcoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.023

Prognostic factors in uterine leiomyosarcoma. A clinical and histopathological study of 143 cases. The Radiumhemmet series 1936-1981

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.023

The Prognostic Significance of ‘Stage, Tumor Size, Cellular Atypia and DNA Ploidy in Uterine Leiomyosarcoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.023

Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas: emphasis on impact of lymphadenectomy and oophorectomy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.023

Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.023

Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: Results of a prospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.023

Metastatic uterine leiomyosarcoma regression using an aromatase inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.023

Uterine smooth muscle tumors of uncertain malignant potential (STUMP): a clinicopathologic analysis of 16 cases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.023

Uterine smooth muscle tumor of uncertain malignant potential: a retrospective analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.023

Endometrial stromal tumours of the uterus: a practical approach using conventional morphology and ancillary techniques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.023

Endometrial stromal nodules and endometrial stromal tumors with limited infiltration: a clinicopathologic study of 50 cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.023

Mesenchymal tumours of the uterus. VII. A clinicopathological study of 60 endometrial stromal nodules

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.023

Hormonal treatment of an endometrial stromal nodule followed by local excision

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.023

Primary uterine endometrial stromal neoplasms. A clinicopathologic study of 117 cases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.023

CD10 is a sensitive and diagnostically useful immunohistochemical marker of normal endometrial stroma and of endometrial stromal neoplasms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.023

Utility of CD10 in distinguishing between endometrial stromal sarcoma and uterine smooth muscle tumors: an immunohistochemical comparison of 34 cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.023

An immunohistochemical analysis of endometrial stromal and smooth muscle tumors of the uterus: a study of 54 cases emphasizing the importance of using a panel because of overlap in immunoreactivity for individual antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.023

Use of Histone Deacetylase 8 (HDAC8), a New Marker of Smooth Muscle Differentiation, in the Classification of Mesenchymal Tumors of the Uterus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.023

Uterine tumors resembling ovarian sex cord tumors are polyphenotypic neoplasms with true sex cord differentiation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.023

Expression of oestrogen and progesterone receptors in low-grade endometrial stromal sarcomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.023

Molecular analysis of the JAZF1-JJAZ1 gene fusion by RT-PCR and fluorescence in situ hybridization in endometrial stromal neoplasms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.023

Prognostic parameters in endometrial stromal sarcoma: a clinicopathologic study in 31 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.023

Endometrial stromal sarcoma: a population-based analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.023

Endometrial stromal sarcoma of the uterus: a clinicopathologic, DNA flow cytometric, p53, and mdm-2 analysis of 17 cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.023

Endometrial stromal sarcoma of the uterus: analysis of 25 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.023

Long-term survival of patients given hormonal therapy for metastatic endometrial stromal sarcoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.023

Lymphadenectomy and ovarian preservation in low-grade endometrial stromal sarcoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.023

Ovarian preservation in stage I low-grade endometrial stromal sarcomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.023

Low-grade endometrial stromal sarcoma: hormonal aspects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.023

Clinical study investigating the role of lymphadenectomy, surgical castration and adjuvant hormonal treatment in endometrial stromal sarcoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.023

Endometrial stromal sarcomas and related high-grade sarcomas: immunohistochemical and molecular genetic study of 31 cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.023

Endometrial stromal sarcomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.023

Ifosfamide treatment of recurrent or metastatic endometrial stromal sarcomas previously unexposed to chemotherapy: a study of the Gynecologic Oncology Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.023

Mullerian adenosarcoma of the uterus: a clinicopathologic analysis of 100 cases with a review of the literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.023

Mullerian adenosarcoma: a clinicopathologic and immunohistochemical study of 55 cases challenging the existence of adenofibroma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.023

Mullerian adenosarcomas: an immunophenotypic analysis of 35 cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.023

Adenosarcoma of the uterus: a clinicopathologic, DNA flow cytometric, p53 and mdm-2 analysis of 11 cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.023

Prognostic features of surgical stage I uterine carcinosarcoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.023

Pathologic variables and adjuvant therapy as predictors of recurrence and survival for patients with surgically evaluated carcinosarcoma of the uterus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.023

Malignant mixed müllerian tumor versus high-grade endometrial carcinoma and aggressive variants of endometrial carcinoma: a comparative analysis of survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.023

Clinicopathologic analysis of 187 high-grade endometrial carcinomas of different histologic subtypes: similar outcomes belie distinctive biologic differences

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.023

Is there a difference in outcome between stage I-II endometrial cancer of papillary serous/clear cell and endometrioid FIGO Grade 3 cancer?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.023

Malignant mixed Müllerian tumors of the uterus: analysis of patterns of failure, prognostic factors, and treatment outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.023

Uterine sarcoma: twenty-seven years of experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.023

Clinicopathologic study of 28 uterine leiomyosarcomas with metastasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.023

10.1016/J.YGYNO.2009.09.023

7 January 2021

Identifiers

DOI

1 reference

5 August 2017

1 reference